Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Kato, Motoyasu ^a   Shukuya, Takehito ^a   Takahashi, Fumiyuki ^a   Mori, Keita ^b   Suina, Kentaro ^a   Asao, Tetsuhiko ^a   Kanemaru, Ryota ^a   Honma, Yuichiro ^a   Muraki, Keiko ^a   Sugano, Koji ^a   Shibayama, Rina ^a   Koyama, Ryo ^a   Shimada, Naoko ^a   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Acute exacerbation; Acute lung injury; Idiopathic pulmonary fibrosis; Interstitial pneumonitis; Non small cell lung cancer; Pemetrexed

Indexed keywords

PEMETREXED; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ARTICLE; CANCER SURVIVAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL; VERY ELDERLY; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL; TOXICITY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84903864904     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-508     Document Type: Article

References (22)

1. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004, 91:S3-S10. 2750810, 15340372.
2. Matsushita H, Tanaka S, Saiki Y, Hara M, Nakata K, Tanimura S, Banba J. Lung cancer associated with usual interstitial pneumonia. Pathol Int 1995, 45:925-932. 10.1111/j.1440-1827.1995.tb03417.x, 8808297.
3. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2006, 174:810-816. 10.1164/rccm.200602-163OC, 16809633.
4. Ohno S, Nakaya T, Bando M, Sugiyama Y. Nationwide epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records. Nihon Kokyuki Gakkai Zasshi 2007, 45:759-765.
5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, . on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011, 183:788-824. 10.1164/rccm.2009-040GL, 21471066, on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis.
6. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F, . Japan Thoracic Radiology Group Interstitial lung disease in Japanese patients with lung cancer. Am J Respir Crit Care Med 2008, 177:1348-1357. 10.1164/rccm.200710-1501OC, 18337594, Japan Thoracic Radiology Group.
7. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, Tsuya A, Kaira K, Murakami H, Takahashi T, Endo M, Yamamoto N. The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer. J Thorac Oncol 2011, 6:1242-1246. 10.1097/JTO.0b013e318216ee6b, 21623239.
8. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003, 8:303-306. 10.1634/theoncologist.8-4-303, 12897327.
9. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, Von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1597.
10. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, Kaira K, Murakami H, Takahashi T, Yamamoto N, Endo M. Interstitial Lung Disease Associated with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer. Anticancer Res 2012, 32:1103-1106.
11. Azuma A, Kudo S. High Prevalence of Drug-induced Pneumonia in Japan. JMAJ 2007, 50:405-411.
12. Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, De Marinis F, Simms L, Sugarman KP, Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3451. 10.1200/JCO.2007.15.0375, 18506025.
13. Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008, 14:4206-4212. 10.1158/1078-0432.CCR-07-5143, 18594001.
14. Kuribayashi K, Voss S, Nishiuma S, Arakawa K, Nogi Y, Mikami K, Kudoh S. Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. Lung Cancer 2012, 75:353-359. 10.1016/j.lungcan.2011.08.002, 21890228.
15. Santiago E, Rossi, Jeremy J, Erasmus, Page MA, Thomas A, Sporn, Goodman PC. Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations. RadioGraphics 2000, 20:1245-1259. 10.1148/radiographics.20.5.g00se081245, 10992015.
16. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller NL. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002, 57:292-299. 10.1053/crad.2001.0792, 12014876.
17. Sakamoto S, Kaburaki K, Sakaguchi S, Sano G, Sugino K, Isobe K, Shibuya K, Kurosaki A, Uekusa T, Homma S. A case of pemetrexed-induced acute lung injury. Nihon Kokyuki Gakkai Zasshi 2009, 47:415-420.
18. Nagata K, Kaji R, Tomii K. Fatal Pemetrexed-Induced Lung Injury in Patients with Advanced Mesothelioma A Report of Two Cases. J Thorac Oncol 2010, 5:1714-1715. 10.1097/JTO.0b013e3181f1378e, 20871270.
19. Kim HO, Lee SY, Shim JJ, Kang KH, Shin BK. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer. J Thorac Oncol 2010, 5:401-402. 10.1097/JTO.0b013e3181c5b198, 20186027.
20. Dhakal B, Singh V, Shrestha A, Rao A, Choong N. Pemetrexed induced pneumonitis. Clin Pract 2011, 1:232-233.
21. Hochstrasser A, Benz G, Joerger M, Templeton A, Brutsche M, Fruh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012, 58:84-88. 10.1159/000336131, 22377772.
22. Kim KH, Song SY, Lim KH, Han SS, Kim SH, Cho JH, Park CW, Lee S, Lee HY. Interstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung Cancer. Cancer Res Treat 2013, 45:74-77. 10.4143/crt.2013.45.1.74, 3629367, 23613674.